Evidence map›Paper›PMID 27659802›Full record

ArticleSLAS technology2017

Engineering A11 Minibody-Conjugated, Polypeptide-Based Gold Nanoshells for Prostate Stem Cell Antigen (PSCA)-Targeted Photothermal Therapy.

Kristine M Mayle, Kathryn R Dern, Vincent K Wong, Kevin Y Chen, Shijun Sung, Ke Ding, April R Rodriguez, Scott Knowles, Zachary Taylor, Z Hong Zhou and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SLAS technology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Kristine M Mayle1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Kathryn R Dern1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Vincent K Wong1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Kevin Y Chen1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Shijun Sung2 Department of Electrical Engineering, University of California, Los Angeles, CA, USA.
Ke Ding1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
April R Rodriguez1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Scott Knowles3 Department of Molecular and Medical Pharmacology, University of California, Los Angeles CA, USA.
Zachary Taylor1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Z Hong Zhou1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Warren S Grundfest1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Anna M Wu3 Department of Molecular and Medical Pharmacology, University of California, Los Angeles CA, USA.
Timothy J Deming1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Daniel T Kamei1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
University of California, Los Angeles · USCalifornia NanoSystems Institute · US

Funding

High-Resolution CryoEM Reconstruction of Large ComplexesR01GM071940 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ZHOU, Z HONG · 2006 to 2025
$5.0M
HIGH-END CRYOEM INSTRUMENT FOR UCLA ELECTRON IMAGING CTR FOR NANOMACHINES: AIDSS10RR023057 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHOU, Z HONG · 2006 to 2006
$1.6M
NCRR NIH HHS S10 RR023057NIGMS NIH HHS R01 GM071940
6 · The paper itself

Abstract

Currently, there is no curative treatment for advanced metastatic prostate cancer, and options, such as chemotherapy, are often nonspecific, harming healthy cells and resulting in severe side effects. Attaching targeting ligands to agents used in anticancer therapies has been shown to improve efficacy and reduce nonspecific toxicity. Furthermore, the use of triggered therapies can enable spatial and temporal control over the treatment. Here, we combined an engineered prostate cancer-specific targeting ligand, the A11 minibody, with a novel photothermal therapy agent, polypeptide-based gold nanoshells, which generate heat in response to near-infrared light. We show that the A11 minibody strongly binds to the prostate stem cell antigen that is overexpressed on the surface of metastatic prostate cancer cells. Compared to nonconjugated gold nanoshells, our A11 minibody-conjugated gold nanoshell exhibited significant laser-induced, localized killing of prostate cancer cells in vitro. In addition, we improved upon a comprehensive heat transfer mathematical model that was previously developed by our laboratory. By relaxing some of the assumptions of our earlier model, we were able to generate more accurate predictions for this particular study. Our experimental and theoretical results demonstrate the potential of our novel minibody-conjugated gold nanoshells for metastatic prostate cancer therapy.

Indexed as

Antigens, NeoplasmCell Line, TumorCell SurvivalConvectionGoldGPI-Linked ProteinsHumansHyperthermia, InducedImmunoglobulinsInfrared RaysLow-Level Light TherapyMaleModels, BiologicalModels, TheoreticalMolecular Targeted TherapyNanoshellsAntigens, NeoplasmGoldGPI-Linked ProteinsImmunoglobulinsNeoplasm ProteinsPSCA protein, humangold nanoshellsphotothermal therapypolypeptide vesicles

Identifiers

PMID27659802
PMCPMC6071911
OpenAlexW2523031476

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.